Line 23: | Line 23: | ||
{{Heidelberg/templateus/Imagesection| | {{Heidelberg/templateus/Imagesection| | ||
https://static.igem.org/mediawiki/2017/e/e7/T--Heidelberg--Team_Heidelberg_2017_theologiexy.png| | https://static.igem.org/mediawiki/2017/e/e7/T--Heidelberg--Team_Heidelberg_2017_theologiexy.png| | ||
− | Figue 1: Selection process for improved CYP1A2 variants in directed evolution | + | Figue 1: Selection process for improved CYP1A2 variants in directed evolution experiments| |
The evolutionary circle starts by M13 phages injecting their genome (SP) into bacterial cells, already containing two additional plasmids, AP and MP. The SP encodes CYP1A2 among genes (except geneIII) that are crucial for phage propagation. If through MP activation mutations in the CYP1A2 gene lead to improved CYP1A2 variants the intracellular level of theophylline increases. Theophylline molecules activate the theophylline riboswitch on the AP and thereby enhance geneIII expression. The assembled phages containing the improved CYP1A2 variant can leave the cell and propagate by infecting new cells. | The evolutionary circle starts by M13 phages injecting their genome (SP) into bacterial cells, already containing two additional plasmids, AP and MP. The SP encodes CYP1A2 among genes (except geneIII) that are crucial for phage propagation. If through MP activation mutations in the CYP1A2 gene lead to improved CYP1A2 variants the intracellular level of theophylline increases. Theophylline molecules activate the theophylline riboswitch on the AP and thereby enhance geneIII expression. The assembled phages containing the improved CYP1A2 variant can leave the cell and propagate by infecting new cells. | ||
}} | }} | ||
Line 45: | Line 45: | ||
{{#tag:html| | {{#tag:html| | ||
<h1>Design of evolution circuit</h1> | <h1>Design of evolution circuit</h1> | ||
− | Our evolution circuit for cytochrome engineering works as follows: Bacteriophages infect bacterial cells by introducing their genome. The genome encodes a Selection Plasmid (SP) that contains the human CYP1A2 variant and all necessary components for virus propagation except geneIII. The Accessory Plasmid (AP) codes for geneIII driven by a Psp-tet promoter and contains a riboswitch, located between the promoter and geneIII, which regulates the expression rate of geneIII. The riboswitch on the AP is only active if theophylline reaches a certain concentration within the bacterium. If CYP1A2 is active, caffeine is converted to theophylline and thereby increases the theophylline concentration. Additionally, the AP encodes for the chaperone HDJ-1, which is essential to receive the functional CYP1A2 enzyme (Fig.1). | + | Our evolution circuit for cytochrome engineering works as follows: Bacteriophages infect bacterial cells by introducing their genome. The genome encodes a Selection Plasmid (SP) that contains the human CYP1A2 variant and all necessary components for virus propagation except geneIII. The Accessory Plasmid (AP) codes for geneIII driven by a Psp-tet promoter and contains a riboswitch, located between the promoter and geneIII, which regulates the expression rate of geneIII. The riboswitch on the AP is only active if theophylline reaches a certain concentration within the bacterium. If CYP1A2 is active, caffeine is converted to theophylline and thereby increases the theophylline concentration. Additionally, the AP encodes for the chaperone HDJ-1, which is essential to receive the functional CYP1A2 enzyme <a href="https://2017.igem.org/Team:Heidelberg/Cytochrome_Engineering">(Fig.1)</a>. |
}}}} | }}}} | ||
Revision as of 19:25, 1 November 2017
Cytochrome Engineering
Modulating CYP1A2 product specifity
Introduction
Enzymes, i.e. proteins mediating specific, catalytic functions, are amongst the most powerful molecular machines invented by nature. Since decades, humans utilize naturally occurring enzymes as bio detergents (e.g. in washing powderThe engineering of novel enzymes catalyzing reactions that do not or only inefficiently occur in nature holds great promise for biotechnological production of regenerative fuel, biomaterials and novel pharmaceuticals, e.g. based on Organosilicons. However, so far, enzyme engineering has typically been a time-consuming, elaborate, expensive and inefficient process, usually requiring laborious, iterative trial-and-error optimization of engineered candidates
To accelerate the development of novel enzymes, our team harnessed the engineering strategy nature uses: Evolution.